Sandbox/Alejandro: Difference between revisions

Jump to navigation Jump to search
Line 181: Line 181:
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cryptococcus spp}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cryptococcus spp}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Moderate Severe to Severe Disease
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Liposomal Amphotericin B]] 3 mg/kg/day IV × 1-2 weeks'''''  <br> OR <br> ▸ '''''[[Amphotericin B]] deoxycholate 0.7-1 mg/kg/day IV × 1-2 weeks'''''<br> OR <br> ▸ '''''[[Amphotericin B lipid complex]] 5 mg/kg/day IV × 1-2 weeks'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | FOLLOWED BY
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Itraconazole]] 200 mg PO q12h x ≥12 months'''''  
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Mild to Moderate Disease
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Itraconazole]] 200 mg PO q12h x ≥12 months'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from ''Clin Infect Dis. 2007;45(7):807-25.''<ref name="Wheat-2007">{{Cite journal  | last1 = Wheat | first1 = LJ. | last2 = Freifeld | first2 = AG. | last3 = Kleiman | first3 = MB. | last4 = Baddley | first4 = JW. | last5 = McKinsey | first5 = DS. | last6 = Loyd | first6 = JE. | last7 = Kauffman | first7 = CA. | title = Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. | journal = Clin Infect Dis | volume = 45 | issue = 7 | pages = 807-25 | month = Oct | year = 2007 | doi = 10.1086/521259 | PMID = 17806045 }}</ref></SMALL>
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[['''''
 
|}
|}
|}
|}
Line 197: Line 207:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[['''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Liposomal Amphotericin B]] 3 mg/kg/day x  1- 2 weeks''''' <br> OR <br>
▸ '''''[[Amphotericin B lipid complex]] 5 mg/kg/day x  1- 2 weeks'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | FOLLOWED BY
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Itraconazole]] 200mg q8h x 3 days '''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | FOLLOWED BY
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[['''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Itraconazole]] 200mg q12h x 6-12 months'''''  
|}
|}
|}
|}
Line 211: Line 226:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[▸ '''''[[Acyclovir]] x 7-10 days''''' <br> OR <br>▸ '''''[[Famciclovir]] x 7-10 days''''' <br> OR <br> ▸ '''''[[Valacyclovir]] x 7-10 days'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
Line 225: Line 240:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[['''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Acyclovir]] x 7 days''''' <br> OR <br>▸ '''''[[Famciclovir]] x 7 days''''' <br> OR <br> ▸ '''''[[Valacyclovir]] x 7 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table34" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cytomegalovirus}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ganciclovir]] x 21 days'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''

Revision as of 15:07, 4 June 2014

Neutropenia and Cellular Immune Deficient Patients

▸ Click on the following categories to expand treatment regimens.

Neutropenia

  ▸  Gram-Negative Bacteria

  ▸  Gram-Positive Bacteria

  ▸  Fungi


Cellular Immune Deficiency

Bacteria

  ▸  Nocardia spp

  ▸  Atypical mycobacteria

Fungi

  ▸  Cryptococcus spp

  ▸  Histoplasma spp

Viruses

  ▸  Varicella-zoster virus

  ▸  Herpes simplex virus

  ▸  Cytomegalovirus


Gram-Negative Bacteria
Preferred Regimen
[[
Alternative Regimen
▸ '''''
Gram-Positive Bacteria
Preferred Regimen
Preferred Regimen 2
Alternative Regimen
[[
[
Fungi
Preferred Regimen
[[
Alternative Regimen
[[
Nocardia spp
Preferred Regimen
[[
Alternative Regimen
[[
Atypical mycobacteria
Preferred Regimen
[[
Alternative Regimen
[[
Cryptococcus spp
Preferred Regimen
Moderate Severe to Severe Disease
Liposomal Amphotericin B 3 mg/kg/day IV × 1-2 weeks
OR
Amphotericin B deoxycholate 0.7-1 mg/kg/day IV × 1-2 weeks
OR
Amphotericin B lipid complex 5 mg/kg/day IV × 1-2 weeks
FOLLOWED BY
Itraconazole 200 mg PO q12h x ≥12 months
Mild to Moderate Disease
Itraconazole 200 mg PO q12h x ≥12 months
Adapted from Clin Infect Dis. 2007;45(7):807-25.[1]
Histoplasma spp
Preferred Regimen
Liposomal Amphotericin B 3 mg/kg/day x 1- 2 weeks
OR

Amphotericin B lipid complex 5 mg/kg/day x 1- 2 weeks

FOLLOWED BY
Itraconazole 200mg q8h x 3 days
FOLLOWED BY
Itraconazole 200mg q12h x 6-12 months
Varicella-zoster virus
Preferred Regimen
[[▸ Acyclovir x 7-10 days
OR
Famciclovir x 7-10 days
OR
Valacyclovir x 7-10 days
Alternative Regimen
[[
Herpes simplex virus
Preferred Regimen
Acyclovir x 7 days
OR
Famciclovir x 7 days
OR
Valacyclovir x 7 days
Alternative Regimen
[[
Cytomegalovirus
Preferred Regimen
Ganciclovir x 21 days
Alternative Regimen
[[
  1. Wheat, LJ.; Freifeld, AG.; Kleiman, MB.; Baddley, JW.; McKinsey, DS.; Loyd, JE.; Kauffman, CA. (2007). "Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (7): 807–25. doi:10.1086/521259. PMID 17806045. Unknown parameter |month= ignored (help)